Malignancies in Transplanted Patients (MALTX)

Uppsala University

Status: Completed

Conditions: Neoplasms

Treatments: Other: Referral to a multidisciplinary expert panel at the Uppsala University Hospital after tumor detection; Drug: Switch from calcineurin inhibitor to an mTOR inhibitor

Study type: Observational

Funder types: Other

Identifiers

NCT02241564

MALTX-001

Details and patient eligibility

About

The aim of the project is to improve the overall treatment and outcome of renal, pancreas or liver transplanted patients who have encountered a malignancy by a structured treatment program for diagnosis and treatment of the malignancy, optimization of the immunosuppressive treatment, follow-up and evaluation of the program.

Enrollment: 95 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients willing and capable of giving written informed consent of participation in the project
• Patients with a previous diagnosed or presently diagnosed or reoccurrence of a malignancy (other then basal cell carcinoma)

Exclusion criteria

• Patients with a primary liver cancer as cause of the transplantation

Trial design

95 participants in 1 patient group

Malignancy post transplantation

Treatment:

Other: Referral to a multidisciplinary expert panel at the Uppsala University Hospital after tumor detection

Drug: Switch from calcineurin inhibitor to an mTOR inhibitor